Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

NovoCodex Biopharmaceuticals

Request full access

Engaged in the business of genetic engineering, and cell culture, among others

Huangpu, ChinaFounded 2017Biotech & Life Sciences

About NovoCodex Biopharmaceuticals

NovoCodex Biopharmaceuticals Co., Ltd. is a biopharmaceutical company established in January 2017, operating as a subsidiary of the publicly listed Zhejiang Medicine Co., Ltd. Located in Shaoxing, China, the firm concentrates on the research, development, and manufacturing of innovative biological drugs, primarily for oncology. The company's business model revolves around in-house drug development and strategic collaborations to bring new cancer therapies to market, targeting unmet clinical needs.

NovoCodex possesses end-to-end capabilities, from genetic engineering, cell culture, and toxin synthesis to ADC (Antibody-Drug Conjugate) coupling and preclinical and clinical research. A core technological strength lies in its pioneering use of non-natural amino acids for site-specific protein modification. This technique allows for the precise attachment of toxins to monoclonal antibodies, a key process in creating next-generation ADC drugs. The company has established R&D centers and manufacturing facilities to support its pipeline, including a production base in Guangzhou capable of producing at a commercial scale.

The company's main products are antibody-drug conjugates designed for targeted cancer therapy. A notable product in its pipeline is ARX788 (also referred to as NCB001), an anti-HER2 ADC for treating HER2-positive recurrent breast and gastric cancers. This drug is currently undergoing clinical trials. Another significant pipeline candidate is ARX305, an anti-CD70 ADC developed for CD70-positive cancers like Renal Cell Carcinoma and Multiple Myeloma. NovoCodex's revenue is generated through product sales, licensing agreements, and milestone payments from its collaboration partners. The company collaborates with international biopharmaceutical firms, such as Ambrx, to co-develop and commercialize its assets, sharing responsibilities for different geographical markets. For instance, in its partnership with Ambrx for ARX305, NovoCodex handles development and commercialization in China, while Ambrx is responsible for markets outside of China.

Since its founding, NovoCodex has secured significant funding, including a Series A round of $61.5M and a Series B round of $59.7M, bringing its total raised capital to over $123M from investors like Lilly Asia Ventures, Matrix Partners, and CS Capital. The company has received numerous accolades, including being named a science and technology-based SME in Zhejiang Province.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
20.7/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Mar 2026 $85M $520M Puhua Capital · Prosperity Investment · CITIC Medical & Heath Group · Zhejiang Xinhai Biotechnology ↗
SERIES BOther financing Jul 2022 $55M $220M SDIC Capital · Runtu Touzi ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

NovoCodex Biopharmaceuticals website traffic

Latest recorded traffic for NovoCodex Biopharmaceuticals is 1.3K monthly website visits, up 251.4% over the last three months.

Latest monthly visits1.3K 3-month web change+251.4%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

NovoCodex Biopharmaceuticals in the Huangpu ecosystem

Live from Dealroom

The NovoCodex Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Matrix Partners China
  • Hangzhou Sanhua Hongdao Investment
  • Lilly Asia Ventures
  • CMG-SDIC Capital
  • SDIC Capital
  • Runtu Touzi

Series B and later5 investors entered at this stage

  • Puhua Capital
  • Prosperity Investment
  • CITIC Medical & Heath Group
  • Zhejiang Xinhai Biotechnology
  • Dongguan Financial Holdings
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China · Huangpu HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about NovoCodex Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See NovoCodex Biopharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.